Atlanta Georgia August 6 2024

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001

Atlanta, Georgia – August 6, 2024 –

Alzamend Neuro, a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases, today announced that it has partnered with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001, a next-generation, patented ionic cocrystal formulation of donepezil for the potential treatment of Alzheimer's disease.

The Phase II clinical trial will evaluate the safety and efficacy of AL001 in patients with mild-to-moderate Alzheimer's disease. The trial will be conducted at MGH and will enroll approximately 100 patients. The primary outcome measure will be the change in cognitive function as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog).

AL001 is a novel formulation of donepezil, a medication that is currently approved for the treatment of Alzheimer's disease. Donepezil is a cholinesterase inhibitor that works by increasing the levels of acetylcholine, a neurotransmitter that is important for memory and cognition.

"We are excited to partner with MGH to conduct this Phase II clinical trial of AL001," said Dr. Steven Paul, CEO of Alzamend Neuro. "We believe that AL001 has the potential to be a safe and effective treatment for Alzheimer's disease, and we look forward to seeing the results of this trial."

"We are pleased to be working with Alzamend Neuro on this important clinical trial," said Dr. Reisa Sperling, Director of the Center for Alzheimer Research and Treatment at MGH. "We believe that AL001 has the potential to be a valuable new treatment option for patients with Alzheimer's disease."

Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases. The company's lead product candidate, AL001, is a next-generation, patented ionic cocrystal formulation of donepezil for the potential treatment of Alzheimer's disease.